There's a new comet in the sky, and it's already visible through binoculars
One of the great things about astronomy is that it's full of surprises, especially when it comes to comets — you just can't predict when a new one might pop up. But when one does appear, it gets both amateur and professional astronomers very excited.
And that's why there's a lot of buzz around a recently discovered comet that is now visible through binoculars, if you know where to look.
The comet is so new that it doesn't yet have an official designation, which is provided by the International Astronomical Union's Minor Planet Center (MPC). For now it goes by the name SWAN25F. It's named in part after the SWAN (Solar Wind Anisotropies) camera on board NASA and the European Space Agency's Solar and Heliospheric Observatory (SOHO) spacecraft. It should get an official name soon.
The comet was discovered by Australian amateur astronomer Michael Mattiazzo, who used SWAN images available to the public. He previously used the same method to discover a comet in 2020.
Right now, the SWAN25F can be found in the early morning sky low in the eastern horizon, in the constellation Pegasus. But over the next few weeks, as the comet moves through our solar system, it will rise a little higher in the morning sky.
The comet is so new that the MPC is waiting for additional observations to get more information from it, such as its origin. However, Paul Wiegert, a professor at Western University's department of physics and astronomy in London, Ont., said that at the moment, its believed to come from the furthest reaches of our solar system, called the Oort cloud, where hundreds of millions — or even trillions — of icy objects reside.
SWAN25F, seen here, was photographed by amateur astronomer Rolando Ligustri using a remote telescope in Utah. (Rolandro Ligustri)
The Oort cloud is mind-blowingly far away. The distance from the sun to Earth is roughly 150 million kilometres, and that measurement is called one astronomical unit (AU). The distance from the sun to the Oort cloud is estimated to be anywhere from 2,000 to 5,000 AU.
When and how to see it
If you'd like to see this ancient relic left over from the formation of our solar system, you need a few things.
First, you need to get up early. SWAN25F is currently low on the eastern horizon and visible before sunrise. You can download astronomy apps on your phone that will allow you to search for particular constellations — in this case, Pegasus.
Second, you need a pair of binoculars. At the moment, the comet isn't visible to the naked eye. It's currently at magnitude 8. Visually, the naked eye can only see magnitude 6 in dark-sky locations (in astronomy, brightness is on a scale where lower and negative numbers signify brighter objects).
(CBC News)
Third, you need a bit of luck.
SWAN25F reached its closest point to the sun, called perihelion, some time in February. Now, it's heading toward us, which is in part why it's getting brighter. But whether or not that brightness will continue is unknown. Astronomers are hoping it will become visible to the naked eye by the end of the month.
"We expect it to get brighter, not because it's necessarily getting more solar heating and being more active and producing more of the gasses that we see, but our geometry relative to it, we're going to get closer to it," Wiegert said.
"And all of those details are going to work in its favour. So we're hoping that it's going to get quite a bit brighter over the next month or so."
And that luck also extends to having clear skies.
If the comet does continue to remain intact and not break apart as some do — though it's passed the most dangerous time for this to happen, when its closest to the sun — it should continue to both brighten in the sky and rise higher in the next three weeks.
Amateur astronomer Dan Bartlett imaged SWAN25F from June Lake, Cali., (Dan Bartlett)
But be warned: the comet won't look like the photos you see online, or even in this story. Those images are made by shooting multiple photographs through telescopes and combining them together. Instead, what you'll see through your binoculars will be a faint fuzzy patch of light. And while that may not seem very exciting, just think about how far that object has travelled.
"A new comet is always exciting. They appear unexpectedly. They're quite beautiful. They do tell us a lot, too, about our solar system, and about how the planets formed," Wiegert said. "So, you know, it's a sort of a beautiful addition to our springtime skies."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent sevabertinib (BAY 2927088) is an oral, small molecule, tyrosine kinase inhibitor (TKI) being evaluated as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations. The U.S. Food and Drug Administration (FDA) grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. WHIPPANY, N.J., May 28, 2025--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy. "Patients with HER2-mutant NSCLC are predominantly women, may be of younger age and non-smokers. The FDA's decision to grant Priority Review designation to our application for sevabertinib is a significant milestone that supports our ongoing efforts to develop healthcare solutions that help people living with lung cancer," said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. "If approved, sevabertinib will provide an additional treatment option for previously treated patients with advanced NSCLC harboring a HER2-activating mutation." The NDA for sevabertinib is based on positive results from the ongoing Phase I/II SOHO-01 trial. Results from patients with advanced NSCLC harboring a HER2-activating mutation, who experienced disease progression after ≥1 systemic therapies for advanced disease and were naïve to HER2-targeted therapy.1 The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.2 In 2024, the FDA granted sevabertinib Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. The Breakthrough Therapy designation was supported by preliminary clinical evidence from the SOHO-01 trial. The FDA grants Breakthrough Therapy designation for the evaluation of investigational medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).3 About sevabertinib (BAY 2927088)4Sevabertinib is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is currently being evaluated as a potential new targeted treatment option for patients with NSCLC harboring human epidermal growth factor receptors 2 (HER2) activating mutations. Sevabertinib is also being studied in patients with metastatic or unresectable solid tumors harboring HER2-activating mutations. Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR. Investigational agent sevabertinib is derived from Bayer's strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA. About Non-Small Cell Lung Cancer (NSCLC)Lung cancer is the leading cause of cancer-related deaths in the U.S.5 Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for more than 85% of cases.4 Activating HER2 mutations are found in 2% to 4% of advanced NSCLC.6 80% of people diagnosed with NSCLC have already progressed to advanced stages, which makes it more difficult to treat.7 Patients with HER2-mutant NSCLC currently face limited targeted therapies.8 About Oncology at BayerBayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes several marketed products across diverse indications and multiple compounds in different stages of clinical development. We have a wealth of expertise in areas including Tumor Cell Intrinsic Pathways, Targeted Radionuclide Therapies, and selective Next-Generation Immuno-Oncology. With our portfolio we are advancing cancer treatments from early to metastatic stage, with the goal of extending survival while limiting side effects for the cancer patients we serve. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to © 2025 BayerBAYER and the Bayer Cross are registered trademarks of Bayer. Find more information at Our online press service is just a click away: Follow us on Facebook: Follow us on X: Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References Le X, et al. Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: expansion cohort from the phase I/II SOHO-01 study. Presented at the 2024 IASLC World Conference on Lung Cancer; San Diego, CA, September 7-10, 2024. PL04.03. U.S. Food and Drug Administration. "Priority Review." Accessed April 21, 2025. U.S. Food and Drug Administration. "Breakthrough Therapy." Accessed April 21, 2025. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2). Clinical trial registration No. NCT05099172. Accessed April 21, 2025. American Cancer Society. Key Statistics for Lung Cancer. Accessed April 21, 2025. Nützinger, J, et al. (2023). Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung cancer (Amsterdam, Netherlands), 186, 107385. Yale Medicine. "Non-Small Cell Lung Cancer." Accessed April 21, 2025. Uy NF,et al. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies. Cancers (Basel). 2022 Aug 27;14(17):4155. doi: 10.3390/cancers14174155. PMID: 36077691; PMCID: PMC9454740. View source version on Contacts Media Contact: Polina Miklush, Tel +1 862.431.8817Email:


Business Wire
5 hours ago
- Business Wire
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy. 'Patients with HER2-mutant NSCLC are predominantly women, may be of younger age and non-smokers. The FDA's decision to grant Priority Review designation to our application for sevabertinib is a significant milestone that supports our ongoing efforts to develop healthcare solutions that help people living with lung cancer,' said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. 'If approved, sevabertinib will provide an additional treatment option for previously treated patients with advanced NSCLC harboring a HER2-activating mutation.' The NDA for sevabertinib is based on positive results from the ongoing Phase I/II SOHO-01 trial. Results from patients with advanced NSCLC harboring a HER2-activating mutation, who experienced disease progression after ≥1 systemic therapies for advanced disease and were naïve to HER2-targeted therapy. 1 The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. 2 In 2024, the FDA granted sevabertinib Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. The Breakthrough Therapy designation was supported by preliminary clinical evidence from the SOHO-01 trial. The FDA grants Breakthrough Therapy designation for the evaluation of investigational medicines that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). 3 About sevabertinib (BAY 2927088) 4 Sevabertinib is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is currently being evaluated as a potential new targeted treatment option for patients with NSCLC harboring human epidermal growth factor receptors 2 (HER2) activating mutations. Sevabertinib is also being studied in patients with metastatic or unresectable solid tumors harboring HER2-activating mutations. Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR. Investigational agent sevabertinib is derived from Bayer's strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA. About Non-Small Cell Lung Cancer (NSCLC) Lung cancer is the leading cause of cancer-related deaths in the U.S. 5 Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for more than 85% of cases. 4 Activating HER2 mutations are found in 2% to 4% of advanced NSCLC. 6 80% of people diagnosed with NSCLC have already progressed to advanced stages, which makes it more difficult to treat. 7 Patients with HER2-mutant NSCLC currently face limited targeted therapies. 8 About Oncology at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes several marketed products across diverse indications and multiple compounds in different stages of clinical development. We have a wealth of expertise in areas including Tumor Cell Intrinsic Pathways, Targeted Radionuclide Therapies, and selective Next-Generation Immuno-Oncology. With our portfolio we are advancing cancer treatments from early to metastatic stage, with the goal of extending survival while limiting side effects for the cancer patients we serve. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to © 2025 Bayer BAYER and the Bayer Cross are registered trademarks of Bayer. Find more information at Our online press service is just a click away: Follow us on Facebook: Follow us on X: Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References Le X, et al. Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: expansion cohort from the phase I/II SOHO-01 study. Presented at the 2024 IASLC World Conference on Lung Cancer; San Diego, CA, September 7-10, 2024. PL04.03. U.S. Food and Drug Administration. 'Priority Review.' Accessed April 21, 2025. U.S. Food and Drug Administration. 'Breakthrough Therapy.' Accessed April 21, 2025. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2). Clinical trial registration No. NCT05099172. Accessed April 21, 2025. American Cancer Society. Key Statistics for Lung Cancer. Accessed April 21, 2025. Nützinger, J, et al. (2023). Management of HER2 alterations in non-small cell lung cancer - The past, present, and future. Lung cancer (Amsterdam, Netherlands), 186, 107385. Yale Medicine. 'Non-Small Cell Lung Cancer.' Accessed April 21, 2025. Uy NF,et al. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies. Cancers (Basel). 2022 Aug 27;14(17):4155. doi: 10.3390/cancers14174155. PMID: 36077691; PMCID: PMC9454740.
Yahoo
a day ago
- Yahoo
Scientists Detect Mysterious Object in Deep Solar System
Scientists are intrigued after spotting a highly unusual celestial object lurking at the very edge of our solar system. It's possible the trans-Neptunian object, dubbed 2017 OF201, is large enough to qualify as a dwarf planet, making it an "extreme 'cousin' of Pluto," according to Princeton postdoc Sihao Cheng, who coauthored a yet-to-be-peer-reviewed paper on the findings. The discovery was also confirmed by the International Astronomical Union's Minor Planet Center last week, lending it an aura of growing credibility. It's a particularly intriguing finding, again bolstering the case that the area of our solar system past the orbit of Neptune is far busier than previously thought. Astronomers have long suggested the existence of a ninth planet, dubbed Planet X or Nine, whose immense gravitational pull could be causing trans-Neptunian objects in the region to act unusually. However, the latest findings could challenge the hypothesis, suggesting 2017 OF201, among other objects, could be causing the strange behavior instead. Cheng and his colleagues used advanced computational models to hone in on the mysterious object's unusual trajectory. 2017 OF201 is an outlier thanks to its enormous size and immense distance from the Sun. "The object's aphelion — the farthest point on the orbit from the Sun — is more than 1600 times that of Earth's orbit," said Cheng in a statement about the research. "Meanwhile, its perihelion — the closest point on its orbit to the sun — is 44.5 times that of Earth's orbit, similar to Pluto's orbit." Thanks to its extreme orbit, it takes the planetoid a whopping 25,000 Earth years to complete a journey around the Sun. How it got out there remains a bit of a mystery. "It must have experienced close encounters with a giant planet, causing it to be ejected to a wide orbit," said coauthor and Princeton PhD Eritas Yang in the statement. The team proposes that 2017 OF201 went through a series of complex maneuvers to end up in its unusual trajectory. "There may have been more than one step in its migration," Cheng explained. "It's possible that this object was first ejected to the Oort cloud, the most distant region in our solar system, which is home to many comets, and then sent back." The findings could challenge the Planet Nine hypothesis since 2017 OF201 isn't part of the observed clusters of objects that "cluster in specific orientations," as coauthor and Princeton graduate student Jiaxuan Li said. These clusters have been found to have strange gravitational characteristics, orbiting at a very different angle than the solar system's planets. Intriguingly, there could be plenty of other weird "cousins" of Pluto in the far reaches of the solar system. But spotting them could prove extremely difficult. "2017 OF201 spends only one percent of its orbital time close enough to us to be detectable," Cheng said. "The presence of this single object suggests that there could be another hundred or so other objects with similar orbit and size; they are just too far away to be detectable now." "Even though advances in telescopes have enabled us to explore distant parts of the universe, there is still a great deal to discover about our own solar system," he added. More on Planet Nine: Scientists Say They May Have Spotted a Huge Hidden Planet Deep in Our Solar System